Baxter International Inc Asset Resilience Ratio
Baxter International Inc asset resilience ratio. Baxter International Inc (BAX) has an Asset Resilience Ratio of 9.80% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See BAX defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Baxter International Inc (2009–2025)
Asset resilience ratio of Baxter International Inc from 2009 to 2025. This chart shows how Baxter International Inc's Asset Resilience Ratio has changed over time. Read BAX total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Baxter International Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see BAX asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $1.97 Billion | 9.8% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $1.97 Billion | 9.80% |
Asset Resilience Insights
- Limited Liquidity: Baxter International Inc maintains only 9.80% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Baxter International Inc Industry Peers by Asset Resilience Ratio
Compare Baxter International Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Mark Dynamics Indonesia Tbk PT
JK:MARK |
Medical Instruments & Supplies | 6.64% |
|
Interojo Inc
KQ:119610 |
Medical Instruments & Supplies | 6.55% |
|
Ansell Ltd
AU:ANN |
Medical Instruments & Supplies | 7.53% |
|
Nanosonics Ltd
AU:NAN |
Medical Instruments & Supplies | 46.84% |
|
SDI Ltd
AU:SDI |
Medical Instruments & Supplies | 3.36% |
|
Austco Healthcare Ltd
AU:AHC |
Medical Instruments & Supplies | 15.90% |
|
Trajan Group Holdings Ltd
AU:TRJ |
Medical Instruments & Supplies | 0.29% |
|
Osteopore Ltd
AU:OSX |
Medical Instruments & Supplies | 22.60% |
Baxter International Inc Asset Resilience Ratio by Year (2009–2025)
Baxter International Inc asset resilience ratio by year from 2009 to 2025. The table below shows the annual Asset Resilience Ratio data for Baxter International Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 9.80% | $1.97 Billion | $20.05 Billion | +2.96pp |
| 2024-12-31 | 6.84% | $1.76 Billion | $25.78 Billion | -4.45pp |
| 2023-12-31 | 11.30% | $3.19 Billion | $28.28 Billion | +5.22pp |
| 2022-12-31 | 6.07% | $1.72 Billion | $28.29 Billion | -2.73pp |
| 2021-12-31 | 8.80% | $2.95 Billion | $33.52 Billion | -9.83pp |
| 2020-12-31 | 18.63% | $3.73 Billion | $20.02 Billion | +0.30pp |
| 2019-12-31 | 18.33% | $3.33 Billion | $18.19 Billion | +6.64pp |
| 2018-12-31 | 11.69% | $1.84 Billion | $15.72 Billion | -8.14pp |
| 2017-12-31 | 19.84% | $3.39 Billion | $17.11 Billion | +1.82pp |
| 2016-12-31 | 18.02% | $2.80 Billion | $15.55 Billion | -6.54pp |
| 2015-12-31 | 24.56% | $5.15 Billion | $20.96 Billion | -- |
| 2014-12-31 | 0.00% | $0.00 | $26.14 Billion | -- |
| 2013-12-31 | 0.00% | $0.00 | $25.22 Billion | -- |
| 2012-12-31 | 0.00% | $0.00 | $20.39 Billion | -- |
| 2011-12-31 | 0.00% | $0.00 | $19.07 Billion | -- |
| 2010-12-31 | 0.00% | $0.00 | $17.49 Billion | -- |
| 2009-12-31 | 0.00% | $0.00 | $17.35 Billion | -- |
About Baxter International Inc
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable p… Read more